{"title":"Prognostic significance of baseline liver enzyme patterns in chronic lymphocytic leukemia: a nationwide real-world cohort study.","authors":"Yotam Bronstein, Lior Rokach, Yair Herishanu, Ronen Arbel, Talish Razi, Noy Nachmias","doi":"10.1080/10428194.2026.2711592","DOIUrl":"https://doi.org/10.1080/10428194.2026.2711592","url":null,"abstract":"<p><p>Liver biochemical abnormalities are relatively common at chronic lymphocytic leukemia (CLL) diagnosis, but their prognostic significance is unclear. We conducted a nationwide real-world study of 3448 adults with newly diagnosed CLL in Clalit Health Services, Israel, with liver biochemistry assessed within ±3 months of diagnosis and no documented preexisting liver disease. Cholestatic elevation was defined as elevated alkaline phosphatase and/or gamma-glutamyl transferase; hepatocellular elevation as elevated alanine and/or aspartate aminotransferase. Median follow-up was 74.9 months. Cholestatic and hepatocellular elevations were present in 16.4% and 6.0% of patients, respectively. In multivariable Cox models, cholestatic elevation was independently associated with inferior overall survival (hazard ratio (HR), 1.21; 95% CI, 1.05-1.39; <i>p</i> = 0.008), whereas hepatocellular elevation did not. Neither pattern was independently associated with time to first treatment. Cholestatic elevation was also associated with increased infection-related hospitalization rates and hospitalized days, identifying a clinically vulnerable subgroup at CLL diagnosis.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-12"},"PeriodicalIF":2.1,"publicationDate":"2026-08-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148701898","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Nikki Agarwal, Brenda W Cooper, Ben K Tomlinson, Michael Daunov, Pingfu Fu, Rebecca B Klisovic, Marcos de Lima, Folashade Otegbeye, Yeritza Hernandez-Collazo, Jignesh Dalal, Mari Dallas, Seunghee Margevicius, Ok-Kyong Chaekal, Molly Megan Gallogly, Koen van Besien, Leland Metheny
{"title":"A phase II study of low dose melphalan with thiotepa and fludarabine as preparative regimen for alternative donor transplantation.","authors":"Nikki Agarwal, Brenda W Cooper, Ben K Tomlinson, Michael Daunov, Pingfu Fu, Rebecca B Klisovic, Marcos de Lima, Folashade Otegbeye, Yeritza Hernandez-Collazo, Jignesh Dalal, Mari Dallas, Seunghee Margevicius, Ok-Kyong Chaekal, Molly Megan Gallogly, Koen van Besien, Leland Metheny","doi":"10.1080/10428194.2026.2707893","DOIUrl":"https://doi.org/10.1080/10428194.2026.2707893","url":null,"abstract":"<p><p>We conducted a phase II study of fludarabine, thiotepa, reduced dose melphalan conditioning for allogeneic transplantation using alternate donors. Thirty-eight patients with hematological malignancies were enrolled. Conditioning included fludarabine 160 mg/m<sup>2</sup>, thiotepa 10 mg/kg (dose adjusted to 5 mg/kg for age >60 years) and melphalan 100 mg/m<sup>2</sup>. Sixteen patients (42%) received reduced intensity thiotepa (5 mg/kg). Twenty-one patients (55%) had acute myeloid leukemia, rest had acute lymphoblastic leukemia, myelodysplastic syndrome, myelofibrosis and relapsed high-risk lymphomas. Twenty-eight (74%) underwent haplo-identical transplants-rest received double cord blood grafts. With median follow up of 38 months, Day +100 marrow demonstrated morphologic complete remission in 34/38 evaluable patients. Progression-free survival at 1-, 2- and 3-year was 68%, 63% and 63%, respectively. Overall survival at 1-, 2- and 3-year was 76%, 71% and 64%, respectively. One-year non-relapse mortality was 21% and relapse rate was 11%. Twelve patients received post-transplant maintenance therapy. We conclude that fludarabine/thiotepa/low dose melphalan can induce durable long-term remissions in patients with advanced disease.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-10"},"PeriodicalIF":2.1,"publicationDate":"2026-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148689536","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Atinuke G Oyinbo, Maira A Castaneda-Avila, Jonggyu Baek, Mayra Tisminetzky, Muthalagu Ramanathan, Kate L Lapane, Mara M Epstein
{"title":"Multimorbidity patterns and survival outcomes in older adults with multiple myeloma: findings from SEER-Medicare.","authors":"Atinuke G Oyinbo, Maira A Castaneda-Avila, Jonggyu Baek, Mayra Tisminetzky, Muthalagu Ramanathan, Kate L Lapane, Mara M Epstein","doi":"10.1080/10428194.2026.2711165","DOIUrl":"https://doi.org/10.1080/10428194.2026.2711165","url":null,"abstract":"<p><p>This study examined the association between multimorbidity patterns and survival in patients with multiple myeloma (2007-2017) using SEER-Medicare (<i>n</i> = 7281). We determined survival differences between patients with low severity multimorbidity, concurrent psychiatric/musculoskeletal disorders, and concurrent cardiometabolic/multisystem impairments. Survival probabilities were compared between the pre- and post-novel drug era to account for the impact of novel therapies. The cardiometabolic/multisystem multimorbidity group had an increased risk of overall (adjusted hazard ratio (HR): 1.64, 95% confidence interval (CI): 1.53-1.77) and cancer-specific mortality (adjusted HR: 1.47, 95% CI: 1.32-1.63) than those with low severity multimorbidity. There were no differences in mortality risk between psychiatric/musculoskeletal and low severity multimorbidity patterns. Survival probabilities were more similar between multimorbidity patterns in the post-novel drug era. The findings suggest that older adults with an elevated multimorbidity burden at diagnosis with multiple myeloma have poor survival outcomes and necessitate the development of health interventions to improve their cancer prognosis.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-11"},"PeriodicalIF":2.1,"publicationDate":"2026-08-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148673681","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Heike Pfeifer, Wolfgang Bethge, Stefan Schönland, Lisa Heberling, Leo Ruhnke, Michael Stadler, Dietrich Beelen, Vladan Vučinić, Thomas Burmeister, Matthias Stelljes, Christoph Faul, Alexander Kiani, Knut Wendelin, Rainer Schwerdtfeger, Elisabeth Lange, Boris Kubuschok, Heinz-August Horst, Martin Gramatzki, Hubert Serve, Dieter Hoelzer, Nicola Gökbuget, Oliver G Ottmann, Fabian Lang
{"title":"Efficacy of imatinib maintenance after stem cell transplantation for Ph+/<i>BCR</i>::<i>ABL1</i> positive ALL: long-term outcome of a randomized trial and impact of peritransplant minimal residual disease.","authors":"Heike Pfeifer, Wolfgang Bethge, Stefan Schönland, Lisa Heberling, Leo Ruhnke, Michael Stadler, Dietrich Beelen, Vladan Vučinić, Thomas Burmeister, Matthias Stelljes, Christoph Faul, Alexander Kiani, Knut Wendelin, Rainer Schwerdtfeger, Elisabeth Lange, Boris Kubuschok, Heinz-August Horst, Martin Gramatzki, Hubert Serve, Dieter Hoelzer, Nicola Gökbuget, Oliver G Ottmann, Fabian Lang","doi":"10.1080/10428194.2026.2707442","DOIUrl":"10.1080/10428194.2026.2707442","url":null,"abstract":"<p><p>Tyrosine kinase inhibitors are recommended as maintenance therapy following allogeneic stem cell transplantation (HSCT) for Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL), but optimal medication, dose, and duration remain a subject of ongoing study. We provide the final analysis of a prospective randomized trial comparing prophylactic and minimal residual disease (MRD)-triggered imatinib maintenance. The two patient cohorts did not differ significantly in terms of cumulative incidence of relapse (CIR; 14% vs. 18%), non-relapse mortality (NRM; 12% vs. 11%), leukemia-free survival (LFS) 64% vs. 69%, and overall survival (OS) at 10 years (68% vs. 71%). Endpoints were assessed every 6 weeks within the trial from 4 weeks after SCT until EOS at week 55 and after that according to local standards. In summary, this provides a framework for MRD-based treatment of patients for maintenance after HSCT with excellent long-term outcome after 10 years in both groups.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1-9"},"PeriodicalIF":2.1,"publicationDate":"2026-08-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148664321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leukemia & LymphomaPub Date : 2026-08-01Epub Date: 2026-06-03DOI: 10.1080/10428194.2026.2682291
Tamar Tadmor, Ilana Levy Yurkovski, Natalia Kreiniz, Miguel Gorenberg, Konstantin Gurevich, Gilad Itchaki
{"title":"FDG PET-CT in hairy cell leukemia: defining standard metabolic uptake across disease compartments.","authors":"Tamar Tadmor, Ilana Levy Yurkovski, Natalia Kreiniz, Miguel Gorenberg, Konstantin Gurevich, Gilad Itchaki","doi":"10.1080/10428194.2026.2682291","DOIUrl":"10.1080/10428194.2026.2682291","url":null,"abstract":"","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2019-2022"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148150276","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Systemic corticosteroid-free beclomethasone dipropionate monotherapy for mild acute gastrointestinal graft-versus-host disease after allogeneic hematopoietic cell transplantation.","authors":"Nozomu Yoshino, Shun-Ichi Kimura, Natsuo Shiraishi, Kaisuke Yamamoto, Koki Hashino, Yuya Nakata, Takuto Ishikawa, Tomohiro Meno, Akari Matsuoka, Yuhei Nakamura, Masakatsu Kawamura, Shunto Kawamura, Junko Takeshita, Yukiko Misaki, Kazuki Yoshimura, Kosuke Takano, Yosuke Okada, Ayumi Gomyo, Masaharu Tamaki, Machiko Kusuda, Hideki Nakasone, Shinichi Kako, Yoshinobu Kanda","doi":"10.1080/10428194.2026.2669029","DOIUrl":"10.1080/10428194.2026.2669029","url":null,"abstract":"<p><p>Systemic corticosteroids are the standard initial therapy for gastrointestinal graft-versus-host disease (GI-GVHD), but are associated with increased infectious risk and potential attenuation of graft-versus-leukemia effects. Beclomethasone dipropionate (BDP) has minimal gastrointestinal absorption and may provide localized efficacy, but evidence for monotherapy is limited. We retrospectively analyzed 37 patients who underwent first allogeneic hematopoietic cell transplantation and received oral BDP as initial monotherapy for acute GI-GVHD. Treatment response was assessed at days 28 and 56, and treatment failure was defined as initiation of systemic corticosteroids. All patients had stage 0-1 disease. Upper and lower GI-GVHD were observed in 24 (64.9%) and 13 (35.1%) patients, respectively. Response rates at days 28 and 56 were 62.9% and 65.6%. Treatment failure occurred more frequently in patients with lower GI-GVHD, female-to-male transplantation, and reduced-intensity conditioning. BDP monotherapy may be effective for selected patients with mild GI-GVHD, although careful monitoring is required in high-risk populations.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1917-1926"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147874659","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leukemia & LymphomaPub Date : 2026-08-01Epub Date: 2026-07-10DOI: 10.1080/10428194.2026.2688561
Joshua Richter, Hans C Lee, Sundar Jagannath, Jeffrey A Zonder, James E Hoffman, Zheng-Yi Zhou, Viviana Garcia-Horton, Mirko Fillbrunn, Hongjue Wang, Matthew Mattera, Timothy J Inocencio, Yingxin Xu, James Harnett, Tito Roccia, Glenn S Kroog, Karen Rodriguez Lorenc, Kate Knorr, Qiufei Ma, Naresh Bumma
{"title":"Linvoseltamab versus elranatamab for triple-class exposed relapsed or refractory multiple myeloma: an indirect treatment comparison.","authors":"Joshua Richter, Hans C Lee, Sundar Jagannath, Jeffrey A Zonder, James E Hoffman, Zheng-Yi Zhou, Viviana Garcia-Horton, Mirko Fillbrunn, Hongjue Wang, Matthew Mattera, Timothy J Inocencio, Yingxin Xu, James Harnett, Tito Roccia, Glenn S Kroog, Karen Rodriguez Lorenc, Kate Knorr, Qiufei Ma, Naresh Bumma","doi":"10.1080/10428194.2026.2688561","DOIUrl":"10.1080/10428194.2026.2688561","url":null,"abstract":"<p><p>We conducted unanchored matching-adjusted indirect comparisons (MAICs) of the BCMA × CD3 bispecific antibodies, linvoseltamab and elranatamab, in triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). Patient-level data from BCMA-targeted therapy-naïve patients in LINKER-MM1 (linvoseltamab; NCT03761108; <i>n</i> = 107; data cutoff (DCO): 07/2024; median follow-up: 21.3 months) were matched to MagnetisMM-3 Cohort A (elranatamab; NCT04649359; <i>N</i> = 123; DCO: 09/2024; median follow-up: 33.9 months). Linvoseltamab demonstrated significantly (<i>p</i> < 0.05) higher overall response (71.5% vs. 61.0%) and complete response or better rates (50.5% vs. 37.4%), and numerically higher very good partial response or better rate (65.0% vs. 56.1%; <i>p</i> = 0.09) versus elranatamab. Duration of response (hazard ratio [HR] = 0.82; <i>p</i> = 0.54), progression-free survival (HR = 0.86; <i>p</i> = 0.50), and overall survival (OS) (HR = 0.67; <i>p</i> = 0.08) were numerically but not statistically significantly favorable for linvoseltamab. When measured using restricted mean survival time, OS significantly favored linvoseltamab (difference: 3.47 months; <i>p</i> = 0.04). This MAIC of linvoseltamab versus elranatamab suggests linvoseltamab offers favorable efficacy in TCE RRMM.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"2116-2128"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148422204","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leukemia & LymphomaPub Date : 2026-08-01Epub Date: 2026-06-07DOI: 10.1080/10428194.2026.2678414
Hua-Jay J Cherng, David DeStephano, Patrick Gould, David Sabatino, Alexander D Sanjurjo, Brian Cuzzo, Drew Gerber, Saagar Jain, Gaston Jean-Louis, Kishan Bhatt, Benjamin May, Craig Soderquist, Bachir Alobeid, Justine Kahn, Ahmed Sawas, Andrew Lipsky, Seda Tolu, Jennifer E Amengual, Barbara Pro, Melissa Beauchemin
{"title":"Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic center.","authors":"Hua-Jay J Cherng, David DeStephano, Patrick Gould, David Sabatino, Alexander D Sanjurjo, Brian Cuzzo, Drew Gerber, Saagar Jain, Gaston Jean-Louis, Kishan Bhatt, Benjamin May, Craig Soderquist, Bachir Alobeid, Justine Kahn, Ahmed Sawas, Andrew Lipsky, Seda Tolu, Jennifer E Amengual, Barbara Pro, Melissa Beauchemin","doi":"10.1080/10428194.2026.2678414","DOIUrl":"10.1080/10428194.2026.2678414","url":null,"abstract":"<p><p>Dose intensity is critical in diffuse large B-cell lymphoma (DLBCL) but can be limited by toxicity risk. The influence of treatment intensity, illness burden, and socioeconomic status (SES) on survival in DLBCL has not been evaluated on a patient-level analysis. We performed a retrospective study of 344 patients with DLBCL from an urban academic cancer center; 55% received lower intensity treatment (average relative dose intensity [ARDI] of cyclophosphamide and doxorubicin <0.9). ARDI, performance status (PS), Charlson comorbidity index (CCI), and double expressor lymphoma (DEL) were associated with progression-free (PFS) and overall survival (OS). Lower ARDI was linked to worse illness burden, treatment intolerance, and higher-risk disease features. Lower ARDI was associated with worse PFS (HR 2.59, <i>p</i> < 0.001) and OS (HR 4.26, <i>p</i> < 0.001) as well as DLBCL progression (sHR 1.86 <i>p</i> = 0.004) and non-relapse mortality (NRM) (sHR 5.45 <i>p</i> = 0.001) in competing risks analysis. Comprehensive multidisciplinary care is needed to reduce the risks associated with undertreatment in DLBCL.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1953-1964"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148199497","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Leukemia & LymphomaPub Date : 2026-08-01Epub Date: 2026-05-27DOI: 10.1080/10428194.2026.2674818
Gaurav Agarwal, Rajiv Kumar Tonk, Kavita Sangwan
{"title":"Emerging drug profile: menin inhibitors in NPM1-mutated and KM2A-rearranged acute myeloid leukemia.","authors":"Gaurav Agarwal, Rajiv Kumar Tonk, Kavita Sangwan","doi":"10.1080/10428194.2026.2674818","DOIUrl":"10.1080/10428194.2026.2674818","url":null,"abstract":"<p><p>Understanding the clinical significance of genetic aberrations in acute myeloid leukemia (AML) has led to the development of several specific treatment drugs that have improved clinical outcomes. Recently, several clinical trials have investigated new therapeutic drugs in this context, either alone or in combination with intensive chemotherapy or low-intensity treatments. Among these, menin inhibitors may constitute a new class of targeted treatments for AML caused by mutations in the nucleophosmin 1 (NPM1) gene or rearrangement of the lysine methyltransferase 2 A (KMT2A) gene. Within the class of menin inhibitors, revumenib is the FDA-approved therapy for the R/R AML with NPM1 mutations, as well as for KMT2A gene rearrangements, which received approval in the year 2025 and 2024, respectively. In addition, ziftomenib got approval in 2025 for patients with R/R AML with NPM1 mutations who lack satisfactory alternative treatment options. Currently, several small-molecule menin inhibitors are being tested in combination with conventional therapies. This publication reviews the recent progress in investigating the clinical evidence of menin inhibitors (revumenib, ziftomenib, bleximenib, enzomenib, BMF-219, emilumenib) toward aggressive leukemias, guides future study and optimal treatment for patients with this type of leukemia.</p>","PeriodicalId":18047,"journal":{"name":"Leukemia & Lymphoma","volume":" ","pages":"1860-1876"},"PeriodicalIF":2.1,"publicationDate":"2026-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148031937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
